Study summary

Rituximab did not help people come off immunoglobulin

Rituximab randomized trial · 37 people, randomized · Published April 2025, Brain

What was tested

Rituximab, a B-cell-depleting antibody, against placebo, in people with CIDP on immunoglobulin, followed by stopping immunoglobulin.

What they found

• Worsening by month 12 was similar: 63.2% with rituximab vs 66.6% with placebo.
• Median time to worsening was 5 vs 2 months (not significant).

What it means

Rituximab may still help specific subgroups, such as people with nodal antibodies, but not CIDP broadly.